Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02499172 · ClinicalTrials.gov registry record · NA
Follow-up of Pregnant Women After a Mass Vaccination of Oral Cholera Vaccine (ShancholTM) in Nsanje Malawi
A NA study, sponsored by Johns Hopkins Bloomberg School of Public Health.
- Terminated
- Registry status
- NA
- Development phase
- 2,758
- Enrollment target
NCT02499172: Clinical Trial NA study, sponsored by Johns Hopkins Bloomberg School of Public Health.
NCT02499172 is a NA study that was terminated before completion, run by Johns Hopkins Bloomberg School of Public Health. The registered enrollment target is 2,758 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02499172, a NA study, was terminated before completion, sponsored by Johns Hopkins Bloomberg School of Public Health.
- TERMINATED
- Registry status
- NA
- Development phase
- 2,758 participants
- Enrollment target
Study Summary
This study, to be carried out immediately following an emergency, reactive cholera vaccination campaign in Nsanje District, Malawi, will be a cohort study to estimate the safety of killed oral cholera vaccine (OCV), in pregnant women as measured by ShancholTM, on pregnancy outcomes and birth defects. While limited evidence which suggests that the vaccine is safe in pregnant women, this setting will allow investigators to answer this question in a community where more than 100,000 people will receive vaccine with no restrictions on pregnancy status. In past cholera vaccine campaigns including clinical trials, pregnant women were excluded due to lack of safety data. However, in this campaign, the decision by the Ministry of Health is that the benefits of offering vaccine to all individuals regardless of pregnancy status far outweigh any theoretical risk. Here the investigators specifically propose to: Specific Objective 1: To conduct surveillance of pregnant women to detect adverse pregnancy outcomes within communities in Nsanje District, Malawi that received oral cholera vaccine in a reactive vaccination campaign that started on 30 March 2015. Through household surveying and enrollment of pregnant women with monthly follow-up visits, the investigators will determine the cumulative incidence of adverse pregnancy outcomes among vaccinated and unvaccinated women in Nsanje and Chikwawa Districts, Malawi. Specific Objective 2: To compare the cumulative incidence of pregnancy loss (miscarriage and stillbirth) of women who received oral cholera vaccine while they were pregnant to women who were vaccinated and became pregnant after the end of the final round of vaccination in Nsanje and Chikwawa Districts, Malawi. Specific Objective 3: To compare the incidence of newborn malformations in a cohort of infants that had fetal exposure to oral cholera vaccine compared to those without such exposure in Nsanje and Chikwawa Districts, Malawi.
Primary Outcome
The primary analysis will compare adverse pregnancy outcome (miscarriage and stillbirth) in Cohorts 1 and 3.
Interventions
- BIOLOGICAL Shanchol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,758 participants |
| Start Date | 2015-06 |
| Est. Completion | 2016-10-30 |
| Phase | NA |
Why NCT02499172 stopped before completion
NCT02499172 is an interventional study that assigns participants to a tested intervention. Its 2,758 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% higher).
The record links to 0 conditions, and to 1 intervention - of which Shanchol is the first listed.
NCT02499172 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02499172 about?
NCT02499172 is a clinical study titled "Follow-up of Pregnant Women After a Mass Vaccination of Oral Cholera Vaccine (ShancholTM) in Nsanje Malawi". This study, to be carried out immediately following an emergency, reactive cholera vaccination campaign in Nsanje District, Malawi, will be a cohort study to estimate the safety of killed oral cholera vaccine (OCV), in pregnant women as measured by ShancholTM, on pregnancy outcomes and birth defects...
What is the current status of trial NCT02499172?
This trial is currently terminated. It is a NA study. The enrollment target is 2,758 participants. The study started on 2015-06. Estimated completion is 2016-10-30.
What interventions are being tested in trial NCT02499172?
The interventions under investigation include: Shanchol (BIOLOGICAL).
Who is sponsoring clinical trial NCT02499172?
This trial is sponsored by Johns Hopkins Bloomberg School of Public Health, which has 187 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02499172's enrollment target sits among peer trials
2,758 44th of 2000 higher than 1,957 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05443737 · 2,800 participants · Phase 3
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
- NCT05899439 · 2,800 participants
Immune Function and the Progression to T1D
- NCT06089109 · 2,800 participants · NA
Creating VIP Corps to Reduce Maternal Deaths
- NCT06345339 · 2,800 participants · Phase 2
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia